Dan Groman - 22 May 2023 Form 4 Insider Report for Enfusion, Inc.

Signature
/s/ Matthew Campobasso, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
22 May 2023
Net transactions value
-$426,516
Form type
4
Filing time
24 May 2023, 16:16:11 UTC
Previous filing
12 May 2023
Next filing
26 May 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENFN Class A Common Stock Sale $31,016 -3,877 -4.9% $8.00 75,932 22 May 2023 Direct F1
transaction ENFN Class A Common Stock Sale $395,500 -50,000 -66% $7.91 25,932 22 May 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on December 14, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.90 to $7.97. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.